hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06385002 id: 2024-0158 briefTitle: Effect of Combined Administration of Sevoflurane and Remimazolam on Emergence overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-05-31 date: 2025-05-31 date: 2024-04-25 date: 2024-04-26 name: Pusan National University Yangsan Hospital class: OTHER briefSummary: Enhanced recovery after surgery (ERAS) protocols are being explored to improve patient outcomes. The method of inducing anesthesia and maintenance using inhalation anesthetics is common but may delay recovery. Remimazolam, a benzodiazepine-class drug, is noted for its rapid metabolism and fewer hemodynamic changes. Research suggests combining sevoflurane and propofol for anesthesia in adults enhances recovery, while studies in pediatric patients indicate a reduction in emergence agitation with remimazolam. However, the impact of combining sevoflurane and remimazolam on postoperative recovery in adult patients undergoing gynecologic and laparoscopic surgery is not yet studied. The study aims to compare the time to emergence from anesthesia and tracheal extubation between concurrent sevoflurane and remimazolam administration versus sevoflurane alone. conditions: Gynecological Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Remimazolam measure: time to emergence measure: time to tracheal extubation measure: usage of vasopressors measure: severity of cough measure: time to discharge from the recovery room measure: postoperative pain scores measure: scores for postoperative nausea and vomiting sex: FEMALE minimumAge: 19 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384989 id: MinnesotaHealthSolutions_LL briefTitle: Safety-Enhancing Motor Vehicle Child Safety Seat overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-07-01 date: 2024-08-15 date: 2024-04-25 date: 2024-04-25 name: Minnesota HealthSolutions class: INDUSTRY briefSummary: This study aims to assess the usability of a load leg design for caregivers who must install the child safety seat into a vehicle. The specific aims are to quantify any errors committed by the participants while installing the car seat and to assess participants' opinions on the car seat's load leg design. conditions: Motor Vehicle Injury conditions: Safety Issues studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Child restraint system with load leg feature measure: Correct use of load leg measure: Load leg error types measure: Other installation errors measure: Opinion on load leg design and instructions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Ohio State University city: Columbus state: Ohio zip: 43210 country: United States name: Julie Mansfield, PhD role: CONTACT phone: 614-366-2101 email: julie.mansfield@osumc.edu lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06384976 id: KYV101-007 briefTitle: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2029-01 date: 2024-04-25 date: 2024-04-25 name: Kyverna Therapeutics class: INDUSTRY briefSummary: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis conditions: Multiple Sclerosis, Primary Progressive conditions: Multiple Sclerosis, Secondary Progressive conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: KYV-101 name: Standard lymphodepletion regimen name: Anti-CD20 mAB measure: To evaluate efficacy of KYV-101 measure: To characterize the safety and tolerability of KYV-101 measure: To characterize the safety and tolerability of KYV-101 measure: To characterize the safety and tolerability of KYV-101 measure: To evaluate efficacy of KYV-101 measure: To characterize the pharmacokinetics (PK) measure: To characterize the pharmacokinetics (PK) measure: To characterize the Pharmacodynamics (PD) measure: To characterize the Pharmacodynamics (PD) measure: To evaluate the immunogenicity (humoral response) of KYV-101 sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06384963 id: Cer22/02 briefTitle: Respiratory Sinus Arrhythmia Pacing Post-CABG Surgery in Patients With HFrEF acronym: RSA-PACE overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-03-01 date: 2025-04-01 date: 2024-04-25 date: 2024-04-25 name: Ceryx Medical Australia class: INDUSTRY name: Avania briefSummary: The goal of this clinical trial is to test a new type of pacemaker in heart failure patients following a heart bypass operation. The new pacemaker restores respiratory sinus arrhythmia which is a natural pattern where the heart rate increases when the participants breathe in and slows down when participants breathe out.
Participants will have a range of tests before their operation and during their recovery in hospital while participants have the new type of pacemaker in place, and will be monitored very closely. Participants will also receive a phone call 1 month after their surgery. Researchers will compare the new type of heart pacing against standard treatment to see if it is as safe, and if it is any better for patients. conditions: Heart Failure With Reduced Ejection Fraction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: Atrial pacing with respiratory sinus arrhythmia (RSA) variability name: Monotonic right atrial overdrive pacing measure: Number of arrhythmia episodes per patient during pacing sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Waikato Hospital city: Hamilton zip: 3240 country: New Zealand name: Martin Stiles, MB ChB role: CONTACT phone: +64 07 957 6080 email: martin.stiles@waikatodhb.health.nz name: Kelly Henderson, BSc role: CONTACT phone: +64 0272564243 phoneExt: 25015 email: Kelly.Henderson@waikatodhb.health.nz lat: -37.78333 lon: 175.28333 hasResults: False
nctId: NCT06384950 id: 2023-11-005A briefTitle: Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma overallStatus: RECRUITING date: 2024-03-22 date: 2024-11-29 date: 2025-03-21 date: 2024-04-25 date: 2024-04-25 name: Taipei Veterans General Hospital, Taiwan class: OTHER_GOV briefSummary: Liver cancer is a leading cause of cancer-related deaths in Taiwan, with its onset linked to factors like chronic liver conditions, cirrhosis, and genetic predispositions. According to the "Barcelona Clinic Liver Cancer (BCLC)" classification, early-stage liver cancer is demarcated by stages 0 to A. Upon such diagnosis, both patients and their families often have numerous questions and concerns, ranging from treatment choices to long-term outcomes. The research proposes a GPT-3.5-based chatbot to assist these patients by providing timely, personalized information, aiming to enrich their understanding of the disease and improve communication between patients and health professionals.
The research methodology employs a Randomized Controlled Trial (RCT) design, dividing participants into a control cohort receiving standard patient education routine and an experimental cohort receiving both the AI chatbot and traditional education routine. The comparative analysis of these cohorts will determine the effectiveness of the AI intervention in improving patients' health literacy and satisfaction. conditions: Carcinoma, Hepatocellular studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: To compare the educational effectiveness of a chatbot integrated with health education information to traditional health education methods. This comparison encompassed aspects such as the patient's health literacy and clinical satisfaction. Based on the findings, recommendations and improvements would be proposed to promote the application and development of large language models in the medical field. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: The research uses a Randomized Controlled Trial (RCT) methodology, dividing patients into a control group undergoing the conventional patient education routine, and an experimental group that leverages both the chatbot and traditional education. By comparing selected outcomes between the two groups, the experiment's effectiveness will be determined. whoMasked: PARTICIPANT count: 450 type: ESTIMATED name: ChatGPT name: patient education with traditional methods. measure: Health literacy score of patients measure: Satisfaction score with medical care measure: Degree of patient anxiety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Veterans General Hospital status: RECRUITING city: Taipei state: Beitou District zip: 11217 country: Taiwan name: Chun-Ying Wu role: CONTACT phone: +886-28712121 phoneExt: 4190 email: chptaiwan07@gmail.com name: HSIAO-PING CHEN role: CONTACT phone: +886-28712121 phoneExt: 4190 email: chptaiwan07@gmail.com lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06384924 id: SBU-RAMAN-SKINCANCER briefTitle: Raman Spectroscopy and Skin Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-30 date: 2025-04-30 date: 2024-04-25 date: 2024-04-25 name: Renee Cattell class: OTHER briefSummary: The goal of this observational study is to find out if Raman Spectroscopy, a type of imaging, can be used to determine the size of skin cancer tumors. The main question it aims to answer is:
This study will take measurements using laser light from an experimental, handheld probe by lightly touching the skin. conditions: Skin Cancer conditions: Basal Cell Carcinoma conditions: Squamous Cell Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Raman Spectroscopy handheld probe (EmVision, FL, USA) name: Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA) measure: Feasibility of Raman Spectroscopy to observe differences in Raman spectra between visible lesion, skin surrounding lesion and contralateral normal skin. measure: Compare the size of clinically defined margin and Raman-defined margin measure: Compare the dose delivered to surrounding critical structures when using clinically defined margin and Raman-defined margin sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stony Brook Hospital city: Stony Brook state: New York zip: 11794 country: United States name: Renee Cattell, PhD role: CONTACT email: renee.cattell@stonybrookmedicine.edu name: Renee Cattell, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.92565 lon: -73.14094 hasResults: False
nctId: NCT06384911 id: STUDY00004543 briefTitle: InvesT1D: Promoting Adolescent Investment in Diabetes Care overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-08 date: 2028-02 date: 2024-04-25 date: 2024-04-25 name: Seattle Children's Hospital class: OTHER name: Harvard Pilgrim Health Care briefSummary: The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes.
Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management and clinical outcomes goals during the study. Researchers will compare changes in glucose levels and person-reported outcomes between groups. conditions: Type 1 Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 96 type: ESTIMATED name: Financial Incentives Program measure: Time In Range measure: Time Above Range measure: Time Below Range measure: Hemoglobin A1c (HbA1c) measure: Diabetes Distress measure: Diabetes Family Conflict measure: Adolescent Quality of Life measure: Caregiver Quality of Life measure: Diabetic Ketoacidosis measure: Severe Hypoglycemia measure: Insulin Adminstration sex: ALL minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06384898 id: STUDY00002259 id: UH3AT012413 type: OTHER_GRANT domain: National Center for Complementary and Integrative Health briefTitle: Remote Tai Chi for Knee Osteoarthritis acronym: TAICHIKNEE overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-12 date: 2027-10 date: 2024-04-25 date: 2024-04-25 name: Tufts Medical Center class: OTHER name: Boston Medical Center name: University of California, Los Angeles name: The Cleveland Clinic name: National Center for Complementary and Integrative Health (NCCIH) briefSummary: The goal of this pragmatic randomized trial is to evaluate the effectiveness of remote Tai Chi to treat knee pain in adults with knee osteoarthritis. The main questions the trial aims to answer are:
Researchers will compare remote Tai Chi added to routine care to routine care alone to see if remote tai chi works to treat knee osteoarthritis pain. Participants will participate in remotely delivered web-based tai chi sessions, twice a week for 12 weeks, or will continue to receive routine care. Participants will be followed for 12 months after randomization. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study is an individually randomized group-treatment (IRGT) trial. Individuals randomly allocated to remote Tai Chi receive the intervention with other participants through an instructor. primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 480 type: ESTIMATED name: Remote Tai Chi measure: PROMIS Pain Interference score measure: PROMIS Pain Interference score measure: PROMIS Pain Interference score measure: WOMAC total score measure: WOMAC total score measure: WOMAC total score measure: SF-12 PCS score measure: SF-12 PCS score measure: SF-12 PCS score measure: Number of knee joint injections measure: WOMAC Pain Score measure: WOMAC Pain Score measure: WOMAC Pain Score measure: WOMAC Pain Score on nominated activity chosen at baseline measure: WOMAC Pain Score on nominated activity chosen at baseline measure: WOMAC Pain Score on nominated activity chosen at baseline measure: WOMAC function score measure: WOMAC function score measure: WOMAC function score measure: WOMAC stiffness score measure: WOMAC stiffness score measure: WOMAC stiffness score measure: Patient's global assessment score measure: Patient's global assessment score measure: Patient's global assessment score measure: PROMIS sleep disturbance OA Knee- Short Form 6a measure: PROMIS sleep disturbance OA Knee- Short Form 6a measure: PROMIS sleep disturbance OA Knee- Short Form 6a measure: Beck Depression Inventory-II score measure: Beck Depression Inventory-II score measure: Beck Depression Inventory-II score measure: SF-12 MCS score measure: SF-12 MCS score measure: SF-12 MCS score measure: Receipt of knee surgery measure: OMERACT/OARSI responder measure: OMERACT/OARSI responder measure: OMERACT/OARSI responder measure: Pain medication use measure: Pain medication use measure: Pain medication use sex: ALL minimumAge: 50 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tufts Medical Center city: Boston state: Massachusetts zip: 02111 country: United States name: Sherwood Alexis, MHA, MBA role: CONTACT phone: 617-636-5405 email: sherwood.alexis@tuftsmedicalcenter.org name: Chenchen Wang, MD role: PRINCIPAL_INVESTIGATOR name: Tim McAlindon, MD role: SUB_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06384885 id: 2024-079 briefTitle: Ultrasound Investigation Into Swimming Induced Pulmonary Edema in Open Water Swimming Athletes acronym: SIPE overallStatus: RECRUITING date: 2024-04-15 date: 2025-06-01 date: 2025-12-01 date: 2024-04-25 date: 2024-04-25 name: Rocky Vista University, LLC class: OTHER briefSummary: Swimming-induced pulmonary edema (SIPE) is a potentially life-threatening condition that can affect swimmers of all abilities. The pathophysiology is not well understood and early identification strategies are not established. Handheld ultrasound is a validated tool for the identification of pulmonary edema and is not well-studied in this population. Understanding the incidence of signs of pulmonary edema and its usefulness as a sign of early pulmonary edema would be beneficial This study evaluates triathletes and open water swimmers at endurance events. A validated protocol for lung ultrasound is used to identify the signs of pulmonary edema. The findings will be analyzed for differences in experience level, type of athlete, gender, age, and environmental factors. The findings may then be used in the future to aid in the early identification and treatment of athletes and military personnel in similar situations to decrease morbidity and mortality. conditions: Swimming Induced Pulmonary Edema studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Ultrasound measure: Lung ultrasound sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rocky Vista University status: RECRUITING city: Parker state: Colorado zip: 80012 country: United States name: Kathryn A Vidlock, MD role: CONTACT phone: 651-226-1642 email: kvidlock@rvu.edu name: Brady Patterson role: PRINCIPAL_INVESTIGATOR name: Harrison Steins role: PRINCIPAL_INVESTIGATOR lat: 39.5186 lon: -104.76136 hasResults: False
nctId: NCT06384872 id: 230042_RRI_Interv5 briefTitle: Effect of Shoe Cushioning Position and Properties on Running-related Injury Risk acronym: RRI_Interv5 overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2025-09-30 date: 2025-12-31 date: 2024-04-25 date: 2024-04-26 name: Luxembourg Institute of Health class: OTHER_GOV name: DECATHLON SA briefSummary: The main purpose of this project is to investigate the influence of cushioning material at both the rear and the forepart of running shoes on musculoskeletal complaints in leisure-time runners. Therefore, the objectives are to investigate if
This study consists in a 6-month intervention trial during which leisure-time runners are required to follow their usual training schedule. Before the beginning of the study, the participants will receive a pair of running shoes. The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively. The study shoes will be administered through random allocation. The participants will be required to use these shoes for all running sessions, and only for running activities.
Participants will first fill out a baseline questionnaire. During the intervention, data on running practice will be downloaded from sports watches and their respective app via Strava. Information on the use of the study shoes will be collected via a weekly questionnaire. Participants will be asked to fill out a weekly questionnaire on any musculoskeletal complaints experienced during the past 7 days. A questionnaire on the perception of cushioning will be filled in by the participants at three time points (after 5h of running, 25h of running, and at the end of follow-up).
* Greater perceived cushioning is related to lower injury risk. conditions: Running-related Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Participants will be stratified according to their sex. Two pre-established randomization list will be prepared by a statistician not involved in any other part of the study before the beginning of the study. To ensure allocation concealment, the study groups as well as the shoes will be coded and the randomization lists will be uploaded in the electronic system by an IT specialist who will not be involved in any other part of the study. The electronic system will provide the investigator with a study group code for each participant, according to the randomization lists. The investigator will upload the shoe ID according to shoe size and study group so that a cross validation will be performed by the electronic system. The investigators in charge of the recruitment, follow-up and data validity check, as well as the participants, will be blinded regarding the shoe version distributed. The shoe code will be broken after completion of data analysis. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1068 type: ESTIMATED name: Shoe Cushioning Position and Properties measure: First running-related injury with a duration of minimum one week measure: First one-day time loss running-related injury measure: First running-related musculoskeletal complaint to the lower limb measure: First substantial running-related injury measure: First overuse running-related injury sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Luxembourg Institute of Health city: Strassen zip: 1445 country: Luxembourg name: Laetitia Garcia, Msc role: CONTACT phone: +352 26970957 email: Laetitia.Garcia@lih.lu lat: 49.62056 lon: 6.07333 hasResults: False
nctId: NCT06384859 id: Pending briefTitle: Effectiveness of Extracorporeal Shockwave Therapy Combined With Platelet-rich Plasma in the Treatment of Chronic Insertional Achilles Tendinopathy overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-01 date: 2027-05-01 date: 2024-04-25 date: 2024-04-25 name: Mahidol University class: OTHER briefSummary: The goal of this clinical trial is to learn about the effectiveness of extracorporeal shockwave(ESWT) combined with platelet-rich plasma(PRP) to treat chronic insertional tendinopathy. The main questions it aims to answer are:
* Visit the clinic at 6 weeks, 3 months, 6 months and 1 year after treatment for checkups and record functional score conditions: Insertional Achilles Tendinopathy studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 94 type: ESTIMATED name: ESWT name: PRP measure: VAS measure: VAS-FA measure: FFI measure: FAAM sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ramathibodi hospital city: Ratchathewi state: Bangkok zip: 10400 country: Thailand name: Prapan Wongrungrote, MD role: CONTACT phone: +66 0810688654 email: prapanw197@gmail.com name: Sukij Laohajaroensombat, MD role: CONTACT phone: +66 022011589 email: sukij.lah@mahidol.ac.th lat: 13.759 lon: 100.53358 hasResults: False
nctId: NCT06384846 id: AI ACS briefTitle: AI Algorithms in Prediction of ACS Based on Leukocyte Properties overallStatus: RECRUITING date: 2024-02-01 date: 2026-07-31 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: RobotDreams GmbH class: INDUSTRY briefSummary: The goal of this observational study is to find out if artificial intelligence (AI) can accurately predict acute coronary syndrome (ACS) using data on white blood cells in adults. The main question it aims to answer is: